CORDIS
EU research results

CORDIS

English EN
Entry inhibitors for the treatment of HCV infection

Entry inhibitors for the treatment of HCV infection

Objective

The EI-HCV Network will provide an integrated multidisciplinary and multi-sector training in a range of leading skills relevant to antiviral and immunotherapeutic drug development in the post-genomics era.
The researchers will gain world-class expertise in specialist shortage skills including structural biology, functional genomics (genomic analysis, bioinformatics, transcriptomics) and proteomics. They will also obtain training on a range of specialist instruments (e.g. DNA sequencers, confocal microscopes, gene arrays, mass specs, flow cytometers, bioinformatics clusters, synchrotrons, biophysical instruments etc.). This will be facilitated by an individual-focused and needs-driven structured training program encompassing in-house training, formal courses, workshops and major mobility elements such as training placements. Trainees will have the unique opportunity to be involved in a cross-sector project that will develop antivirals and immuno-therapies from the bench to the bedside. Specifically, the Network will identify new therapeutic interventions for the treatment of hepatitis C virus (HCV) infection.
Chronic HCV infection is frequently associated with severe liver disease including liver cancer. Even the latest treatments are ineffective in a significant proportion of infected individuals. Therefore there is a paramount need to identify new therapies. The Network will: Define HCV receptor binding, fusion and entry events; Determine the structure and functional regions of the HCV glycoproteins and receptors; Isolate and characterise neutralizing monoclonal antibodies and sera; Refine in vitro models to measure infectivity and antiviral effects; Use these advances to develop lead antiviral agents and immuno-therapies suitable for clinical trial.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE UNIVERSITY OF NOTTINGHAM

Address

University Park
Nottingham

United Kingdom

Administrative Contact

Jonathan BALL (Dr)

Participants (13)

Sort alphabetically

Expand all

CEINGE BIOTECNOLOGIE AVANZATE SCARL

Italy

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

France

HOSPITAL CLINIC I PROVINCIAL DE BARCELONA

Spain

INSTITUT PASTEUR

France

ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE "P. ANGELETTI" SPA

Italy

KAROLINSKA INSTITUTET

Sweden

MEDICAL RESEARCH COUNCIL

United Kingdom

MEDICAL RESEARCH COUNCIL TECHNOLOGY

United Kingdom

MOLECULES OF MAN AB

Sweden

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

UNIVERSITAET ROSTOCK

Germany

UNIVERSITAETSKLINIKUM HEIDELBERG

Germany

UNIWERSYTET GDANSKI.

Poland

Project information

Grant agreement ID: 35599

  • Start date

    1 October 2006

  • End date

    30 September 2010

Funded under:

FP6-MOBILITY

  • Overall budget:

    € 1 971 284

  • EU contribution

    € 3 507 650

Coordinated by:

THE UNIVERSITY OF NOTTINGHAM

United Kingdom